Biomedical Research and Therapy <p>Biomedical Research and Therapy - The Vietnamese Journal of Medicine fully open access journal of original research across a broad spectrum of medical scientific disciplines and sub-specialties. An international peer-reviewed journal, it publishes high quality open access research articles with a special emphasis on basic, translational and clinical research into molecular therapeutics and cellular therapies, including animal models and clinical trials. The peer-review process will only accept content that is scientifically, technically and ethically sound, and in compliance with standard reporting guidelines.</p> <p>Biomedical Research and Therapy's Editorial Policies follow the recommendations of the <a href="" target="_blank" rel="noopener">International Committee of Medical Journal Editors (ICMJE)</a>, <a href="" target="_blank" rel="noopener">the World Association of Medical Editors (WAME)</a>, and&nbsp;<a href="" target="_blank" rel="noopener">the Committee on Publication Ethics (COPE)</a> for guidance on policies and procedures related to publication ethics.&nbsp;</p> <p>The journal is published monthly, 12 issues per year.</p> <p>&nbsp;</p> <h1 class="sc-gPEVay iUuzmH sc-gacfCG kuiQoX hero_banner_title heading-title">COVID-19 collection</h1> <p><a href="" target="_blank" rel="noopener"><img src="/public/site/images/pvphuc/covid19.jpg" width="184" height="85"></a></p> <div class="sc-dEfkYy cKZZYG hero_banner_text">A collection of new and previously published articles on coronavirus research and treatment. Please click <strong><a href="" target="_blank" rel="noopener">here</a></strong>.</div> <p>&nbsp;</p> BioMedPress (BMP) en-US Biomedical Research and Therapy 2198-4093 <p>Copyright The Author(s) 2017. This article is published with open access by <a href="" target="_blank">BioMedPress</a>. This article is distributed under the terms of the&nbsp;<a href="" target="_blank">Creative Commons Attribution License (CC-BY 4.0)</a> which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.&nbsp;</p> Expression of P16 biomarker in squamous cell carcinoma of uterine cervix and its association with clinico-pathological parameters: A cross-sectional study <p><strong>Introduction</strong>: Cervical cancer is the most common cancer among females. P16 is the surrogate marker for cervical carcinoma. This study aimed to evaluate the association of P16 marker with clinic-pathological parameters in squamous cell carcinoma of uterine cervix.</p> <p><strong>Methods</strong>: This was a cross-sectional study. Histological confirmed cases of squamous cell carcinoma (SCC) of cervix were considered. All cases were evaluated for IHC P16 expression as per lower anogenital squamous terminology (LAST) criteria and correlated with clinico-pathological parameters. The data was analyzed by SPSS software version 22.</p> <p><strong>Results</strong>: Out of 75 cases, P16 biomarker expression was block positive, ambiguous and negative in 67 (89.3%), 5 (6.6%), and 3 (4%) cases, respectively. There was a significant association between P16 expression and age (p = 0.005). All cases between 30-59 years of age showed block positivity. There was no significant association between P16 expression and age at marriage (p = 0.951), age at menopause (p = 0.311), parity (p = 0.554), clinical symptoms/signs, stage of disease (p = 0.28), or histopathological grade (p = 0.877). Maximum expression was seen between 40-44 years. Moreover, all cases having 1 &amp; 2 parity showed block positivity and all stage I cases showed block positivity.</p> <p><strong>Conclusion</strong>: P16 biomarker was significantly expressed in cervical cancers of the relatively younger age group and those with early stage of disease.</p> Kalyani R. Raghuveer C.V. Sheela S.R. ##submission.copyrightStatement## 2020-09-25 2020-09-25 7 9 3954 3961 10.15419/bmrat.v7i9.626 title description none g